Search Result
Results for "
p300
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-132197
-
|
Epigenetic Reader Domain
Histone Acetyltransferase
|
Cancer
|
CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC50 of 166 nM) and CBP inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC50 of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450 .
|
-
-
- HY-146445
-
|
Epigenetic Reader Domain
Histone Acetyltransferase
|
Cancer
|
P300 bromodomain-IN-1 (Compoun 1u) is a potent p300 (EP300) bromodomain inhibitor with an IC50 of 49 nM. P300 bromodomain-IN-1 suppresses the expression of c-Myc and induces G1/G0 phase arrest and apoptosis in OPM-2 cells .
|
-
-
- HY-134621
-
-
-
- HY-139861
-
-
-
- HY-151812
-
-
-
- HY-146277
-
|
Histone Acetyltransferase
|
Cancer
|
CBP/p300-IN-19 is a potent p300/CBP HAT inhibitor with IC50s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 shows antitumor activity .
|
-
-
- HY-146277A
-
|
Histone Acetyltransferase
|
Cancer
|
CBP/p300-IN-19 hydrochloride is a potent and selective p300/CBP HAT inhibitor with IC50s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 hydrochloride shows antitumor activity .
|
-
-
- HY-155229
-
-
-
- HY-128876
-
-
-
- HY-138536
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC CBP/P300 Degrader-1 is a potent PROTAC CBP/P300 degrader. PROTAC CBP/P300 Degrader-1 potently inhibited cell viability of multiple cancer cell lines .
|
-
-
- HY-100132
-
|
Histone Acetyltransferase
|
Cancer
|
P300/CBP-IN-5 is a potent p300/CBP histone acetyltransferase inhibitor extracted from patent WO2016044770A1, Example 715, has an IC50 of 18.8 nM .
|
-
-
- HY-143339
-
|
Epigenetic Reader Domain
Histone Acetyltransferase
|
Cancer
|
CBP/p300-IN-15 (compound 13a) is a potent p300/CBP inhibitor, with IC50 values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC50 values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research .
|
-
-
- HY-128875
-
|
Histone Acetyltransferase
|
Cancer
|
CBP/p300-IN-10 is a highly potent histone acetyltransferase EP300 and CREBBP with IC50 values of 26 nM and 39 nM, respectively. CBP/p300-IN-10 can be used to research anticancer .
|
-
-
- HY-136920
-
|
Epigenetic Reader Domain
|
Cancer
|
CBP/p300-IN-8 is a potent inhibitor of the CBP/P300 family of bromodomains. CBP/p300-IN-8 inhibits CBP (IC50=0.01-0.1 µΜ) and BRD4 (IC50=1-1000 µΜ) activity .
|
-
-
- HY-111420
-
-
-
- HY-138539
-
-
-
- HY-139707
-
-
-
- HY-139108
-
|
Histone Acetyltransferase
Apoptosis
|
Cancer
|
DCH36_06 is a potent and selective p300/CBP inhibitor with IC50s of 0.6 μM and 3.2 μM for p300 and CBP, respectively. DCH36_06 mediated p300/CBP inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity .
|
-
-
- HY-143441
-
|
Histone Acetyltransferase
|
Cancer
|
CBP/p300-IN-17 (compound 7) is a potent EP300/CBP HAT inhibitor with IC50s of 0.18, 0.69 µM for HAT EP300 and LK2 H3K27, respectively .
|
-
-
- HY-143442
-
|
Histone Acetyltransferase
|
Cancer
|
CBP/p300-IN-18 (compound 8) is a potent EP300/CBP HAT inhibitor with IC50s of 0.056, 0.46 µM for HAT EP300 and LK2 H3K27, respectively .
|
-
-
- HY-143440
-
|
Histone Acetyltransferase
|
Cancer
|
CBP/p300-IN-16 (compound 1) is a potent EP300/CBP HAT inhibitor with IC50s of 0.61, 2.24 µM for HAT EP300 and LK2 H3K27, respectively .
|
-
-
- HY-136938
-
EP31670
|
Epigenetic Reader Domain
Histone Acetyltransferase
|
Cancer
|
NEO2734 (EP31670) is an orally active dual p300/CBP and BET bromodomain selective inhibitor, with IC50 values of <30 nM for both p300/CBP and BET bromodomains . NEO2734 is active in SPOP mutant and wild-type prostate cancer .
|
-
-
- HY-131035
-
|
Histone Acetyltransferase
|
Cancer
|
Lys-CoA TFA is a selective p300 histone acetyltransferase (HAT) inhibitor (IC50=50-500 nM). Lys-CoA TFA displays >100-fold selectivity for p300 over PCAF (IC50=200 μM). Lys-CoA TFA inhibits p300 HAT activity-dependent transcriptional activation .
|
-
-
- HY-147261
-
|
Histone Acetyltransferase
|
Cancer
|
B026 is a selective, potent, orally active p300/CBP histone acetyltransferase (HAT) inhibitor with IC50 values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines .
|
-
-
- HY-115539
-
|
Wnt
β-catenin
Histone Acetyltransferase
|
Cancer
|
Windorphen is a Wnt/β-catenin signal inhibitor that specifically targets the function of the c-terminal transactivation domain of β-catenin-1 but not β-catenin-2. Windorphen selectively targets p300, disrupting the association of the mammalian β-catenin with p300 but not CBP .
|
-
-
- HY-162259
-
|
PROTACs
Histone Acetyltransferase
|
Cancer
|
QC-182 is a potent PROTAC degrader of p300/CBP. QC-182 reduces p300 protein in the SK-HEP-1 cells (DC50 = 93nM). QC-182 potently and effectively inhibits cell growth in the SK-HEP-1 and JHH7 cell lines with IC50 values of 0.733 and 0.477 μM, respectively. QC-182 can be used for the research of hepatocellular carcinoma (HCC) .
|
-
-
- HY-134591
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate which can be used for synthesizing dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .
|
-
-
- HY-134592
-
-
-
- HY-128761
-
|
Epigenetic Reader Domain
|
Cancer
|
CBP/EP300-IN-2 is an inhibitor of CBP/EP300 with IC50 values of 1.07 nM and 5.96 nM for CBP/HTRF and Myc, respectively. CBP/EP300-IN-2, example 25, is extracted from patent WO2017205538A1 .
|
-
-
- HY-107455
-
-
-
- HY-134582
-
dCBP-1
1 Publications Verification
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression .
|
-
-
- HY-19541
-
-
-
- HY-N2345
-
|
Histone Acetyltransferase
|
Cancer
|
Procyanidin B3 is a natural product, acts as a specific HAT inhibitor, binds to the other site of p300 instead of the active site, selectively inhibits p300-mediated androgen receptor acetylation. Procyanidin B3 has no effect on HDAC or HMT (histone methyltransferase) .
|
-
-
- HY-120290
-
|
Histone Acetyltransferase
|
Cancer
|
PU141 is a selected pyridoisothiazolone HAT inhibitor. PU141 is selective toward CBP and p300. PU141 induces cellular histone hypoacetylation and inhibits growth of several neoplastic cell lines originating from different tissues. Anticancer activity .
|
-
-
- HY-162128
-
|
Histone Acetyltransferase
|
Cancer
|
Antitumor agent-130 (Compound 7b) is a p300 histone acetyltransferases (HAT) inhibitor with an IC50 of 1.51 μM. Antitumor agent-130 combinates with doxorubicin (HY-15142A) can significantly inhibit tumor growth and invasion in vitro and in vivo .
|
-
-
- HY-124960
-
-
-
- HY-139148
-
-
-
- HY-124696
-
|
Histone Acetyltransferase
|
Cancer
|
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC50s of 8.39, 9.74, 2.49 and 5.35 μM, respectively .
|
-
-
- HY-N0005S
-
-
-
- HY-101125A
-
L-45 dihydrochloride
|
Epigenetic Reader Domain
|
Cancer
|
L-Moses (L-45) dihydrochloride is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a Kd of 126 nM .
|
-
-
- HY-101125
-
L-45
|
|
|
L-Moses (L-45) is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a Kd of 126 nM .
|
-
-
- HY-13823
-
-
-
- HY-111784
-
CCS1477
|
Epigenetic Reader Domain
|
Cancer
|
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with Kd values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a Kd of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression .
|
-
-
- HY-149306
-
|
Histone Acetyltransferase
MDM-2/p53
|
Cancer
|
MS78 is an acetylation targeting chimera (AceTAC) that acetylates the p53 tumor suppressor protein. MS78 recruits histone acetyltransferase p300/CBP to acetylate the p53Y220C mutant. MS78 upregulates TRAIL apoptotic genes and downregulates DNA damage response pathways. MS78 contains a CBP/p300 binder, a p53Y220C binder and a linker .
|
-
-
- HY-141546
-
|
Histone Acetyltransferase
|
Cancer
|
Pocenbrodib (compound II) is a CBP/p300 family of bromodomain inhibitor. Pocenbrodib has the potential for cancer research .
|
-
-
- HY-154984
-
|
Histone Acetyltransferase
PROTACs
|
Cancer
|
JET-209 is a potent PROTAC CBP/p300 degrader, with DC50 values of 0.05 nM and 0.2 nM for CBP and p300. JET-209 contains Lenalidomide (HY-A0003) (the cereblon ligand), a linker and GNE-207 (HY-120028) (bromodomain Inhibitor). JET-209 is used for cancer research .
|
-
-
- HY-124722
-
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
OHM1 is an analog of HIF1α CTAD that inhibits its binding with p300/CBP. OHM1 targets CH1 domain with an affinity of 0.53 μM .
|
-
-
- HY-100697
-
-
-
- HY-134964
-
-
-
- HY-100671
-
|
Histone Acetyltransferase
STAT
|
Inflammation/Immunology
Cancer
|
L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM . L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation . L002 has the potential for hypertension‐induced cardiac hypertrophy and fibrogenesis treatment .
|
-
- HY-136285
-
|
Histone Acetyltransferase
|
Cancer
|
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .
|
-
- HY-15826
-
|
Epigenetic Reader Domain
Histone Acetyltransferase
|
Inflammation/Immunology
Cancer
|
SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (Kds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .
|
-
- HY-110263
-
-
- HY-N2020
-
-
- HY-145386
-
|
Others
|
Cancer
|
(S,S)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .
|
-
- HY-136285A
-
|
Others
|
Cancer
|
(R,R)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .
|
-
- HY-147290
-
|
Histone Acetyltransferase
|
Cancer
|
NSC 694623 is a potent histone acetyltransferase (HAT) inhibitor with an IC50 value of 15.9 μM for recombinant HAT p300/CBP-associated factor (PCAF). NSC 694623 has antiproliferative activity against certain cancer cells. NSC 694623 can be used for researching anticancer .
|
-
- HY-15887
-
-
- HY-153768
-
|
Histone Acetyltransferase
|
Cancer
|
KAT modulator-1 (Compound 3) is a KAT modulator. KAT modulator-1 can interact with p300 full-length but not with the catalytic domain. KAT modulator-1 can be used for epigenetics research .
|
-
- HY-100734
-
|
Histone Acetyltransferase
|
Cancer
|
Histone Acetyltransferase Inhibitor II (compound 2c) is a potent, selective and cell permeable p300 histone acetyltransferase inhibitor, with an IC50 of 5 µM. Histone Acetyltransferase Inhibitor II shows anti-acetylase activity in mammalian cells .
|
-
- HY-W013274
-
|
Histone Acetyltransferase
Apoptosis
|
Cancer
|
CPTH2 is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) .
|
-
- HY-W013274A
-
|
Histone Acetyltransferase
Apoptosis
|
Cancer
|
CPTH2 hydrochloride is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 hydrochloride selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 hydrochloride induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) .
|
-
- HY-N0005
-
Curcumin
Maximum Cited Publications
62 Publications Verification
Diferuloylmethane; Natural Yellow 3; Turmeric yellow
|
Histone Acetyltransferase
Epigenetic Reader Domain
Keap1-Nrf2
Autophagy
Mitophagy
Influenza Virus
Ferroptosis
|
Cancer
|
Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.
|
-
- HY-107569
-
|
Cholinesterase (ChE)
Histone Acetyltransferase
Apoptosis
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50s of 0.66 µM and 7.39 µM, respectively . Garcinol also inhibits histone acetyltransferases (HATs, IC50= 7 μM) and p300/CPB-associated factor (PCAF, IC50 = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity .
|
-
- HY-110127
-
NU9056
2 Publications Verification
|
Histone Acetyltransferase
Apoptosis
|
Cancer
|
NU9056 is a potent and selective Tip60 (KAT5) histone acetyltransferase inhibitor with an of 2 µM. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5. NU9056 induces apoptosis of prostate cancer cells .
|
-
- HY-14428
-
|
β-catenin
Apoptosis
|
Cancer
|
ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.
|
-
- HY-160261S
-
|
Epigenetic Reader Domain
|
Cancer
|
EP300/CBP-IN-2 is a potent EP300/CBP inhibitor that has good activity in vivo. EP300/CBP-IN-2 can be used for the research of cancer .
|
-
- HY-160260
-
|
Epigenetic Reader Domain
Histone Acetyltransferase
|
Cancer
|
EP300/CBP-IN-1 (compound 172) is a potent EP300/CBP inhibitor with IC50s of 2.3 nM and 2.1 nM for CBP BRD and EP300 BRD, respectively. EP300/CBP-IN-1 has the inhibitory effect on the proliferation of prostate cancer CWR22RV1 cells .
|
-
- HY-100726
-
-
- HY-128364
-
|
Histone Acetyltransferase
|
Cancer
|
Ep300/CREBBP-IN-3 (Example 61) is a potent Ep300 and CREBBP inhibitor with IC50s of 0.056 and 0.095 μM, respectively. Ep300/CREBBP-IN-3 can be used for the research of cancer .
|
-
- HY-128367
-
|
Histone Acetyltransferase
|
Cancer
|
Ep300/CREBBP-IN-4 (Example 56) is a potent Ep300 and CREBBP inhibitor with IC50s of 0.024 and 0.064 μM, respectively. Ep300/CREBBP-IN-4 can be used for the research of cancer .
|
-
- HY-128363
-
|
Histone Acetyltransferase
|
Cancer
|
Ep300/CREBBP-IN-2 (Example 73) is a potent and orally active Ep300 and CREBBP inhibitor with IC50s of 0.052 and 0.148 μM, respectively. Ep300/CREBBP-IN-2 can be used for the research of cancer .
|
-
- HY-128362
-
|
Histone Acetyltransferase
|
Cancer
|
Ep300/CREBBP-IN-8 (Example 37) is a potent and orally active Ep300 and CREBBP inhibitor with IC50s of 0.014 and 0.018 μM, respectively. Ep300/CREBBP-IN-8 can be used for the research of cancer .
|
-
- HY-RS04405
-
|
Small Interfering RNA (siRNA)
|
Others
|
EP300 Human Pre-designed siRNA Set A contains three designed siRNAs for EP300 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
EP300 Human Pre-designed siRNA Set A
EP300 Human Pre-designed siRNA Set A
- HY-RS04406
-
|
Small Interfering RNA (siRNA)
|
Others
|
Ep300 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ep300 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Ep300 Mouse Pre-designed siRNA Set A
Ep300 Mouse Pre-designed siRNA Set A
- HY-RS04407
-
|
Small Interfering RNA (siRNA)
|
Others
|
Ep300 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ep300 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Ep300 Rat Pre-designed siRNA Set A
Ep300 Rat Pre-designed siRNA Set A
- HY-19541A
-
|
Epigenetic Reader Domain
|
Cancer
|
I-CBP112 hydrochloride is a selective inhibitor of CBP/P300 that directly binds their bromodomains (Kds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin .
|
-
- HY-145765
-
-
- HY-100482
-
-
- HY-143443
-
|
Histone Acetyltransferase
Histone Demethylase
|
Cancer
|
DS17701585 (Compound 11) is a highly selective, orally active EP300 and CBP inhibitor with IC50 values of 0.040, 0.15, 0.45 and 0.70 µM against CBP, EP300, H3K27 and SOX2. DS17701585 can be used for cancer research .
|
-
- HY-158113
-
|
Histone Acetyltransferase
PROTACs
|
Cancer
|
CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC50 of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC50s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .
|
-
- HY-10593
-
|
Wnt
|
Others
|
IQ 1 is a Wnt/β-catenin/CBP signalling sustainer. IQ 1 maintains long-term expansion of Wnt/β-catenin-driven mouse embryonic stem cells (ESCs) and prevents spontaneous differentiation by enhancing β-catenin/CBP-mediated transcription and preventing conversion to β-catenin/p300-mediated transcription. IQ-1 regulates Wnt signalling by interacting with PR72/130. IQ 1 can be used in study of ESCs expansion .
|
-
- HY-152241
-
|
Histone Acetyltransferase
|
Cancer
|
DS-9300 is a potent, orally active, selective EP300/CBP HAT inhibitor with an IC50 value of 28 nM. DS-9300 has anticancer activity and can be used in prostate cancer disease research .
|
-
- HY-116673
-
|
Histone Acetyltransferase
|
Neurological Disease
|
TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has beneficial implications for the brain functions of neurogenesis and long-term memory .CSP-TTK21 can ameliorate Aβ-impaired long-term potentiation (LTP). CSP-TTK21 may enhance the transcription of genes that promote synaptic health and cognitive function . CSP-TTK21 is orally effective and leads to improvements in motor functions, histone acetylation dynamics in a spinal injury rat model .
|
-
- HY-111422
-
|
Epigenetic Reader Domain
|
Cancer
|
PLX51107 is a potent and selective BET inhibitor, with Kds of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 (Kd, in the 100 nM range).
|
-
- HY-147008
-
|
Epigenetic Reader Domain
|
Cancer
|
XP-524 is a potent BET and EP300 inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC) .
|
-
- HY-19999A
-
|
Epigenetic Reader Domain
Histone Acetyltransferase
|
Neurological Disease
|
PF-CBP1 hydrochloride is a highly selective inhibitor of the CREB binding protein bromodomain (CBP BRD). PF-CBP1 inhibits CREBBP and EP300 bromodomains with IC50 of 125 nM and 363 nM respectively. PF-CBP1 hydrochloride reduces LPS-induced inflammatory cytokines expression (IL-1β, IL-6 and IFN-β) in primary macrophages. PF-CBP1 hydrochloride also downregulates RGS4 expression cortical neurons and can be used for the research of neurological disorders, including epilepsy and parkinson's disease, et al .
|
-
- HY-161250
-
|
PROTACs
|
Cancer
|
Pomalidomide-NH-PEG6-amide-C2-CPI-1612 (compound 22 (dCE-1)) is a CBP/EP300 degrader, which contains a CRBN ligands Pomalidomide, a 24-atom linker with 6 PEG units and a HAT inhibitor CPI-1612. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 exhibits antiproliferative effects in cells multiple myeloma cells LP1 (with a DC50 of 1.2 μM), MM1S and various cancer cell lines, especially the leukemia cells .
|
-
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N0005S
-
|
Curcumin-d6is a deuterium labeled Curcumin (Turmeric yellow). Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase (HATs) and also shows inhibitory effects on NF-κB and MAPKs.
|
-
-
- HY-160261S
-
|
EP300/CBP-IN-2 is a potent EP300/CBP inhibitor that has good activity in vivo. EP300/CBP-IN-2 can be used for the research of cancer .
|
-
Cat. No. |
Product Name |
Application |
Reactivity |
-
- HY-P80775
-
Ep300; p300; Histone acetyltransferase p300; p300 HAT; E1A-associated protein p300
|
ICC/IF, WB, IHC-F, IHC-P, ELISA
|
Human, Mouse, Rat |
p300 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 264 kDa, targeting to p300. It can be used for ICC/IF,WB,IHC-F,IHC-P,ELISA assays with tag free, in the background of Human, Mouse, Rat.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: